secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-262509
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax reports Q3 2025 revenue $45.9M, Revuforj net sales $32M; FDA approval for NPM1m AML on Oct 24
--------------------------------------------------------------------------------

- Total revenue $45.9M (Revuforj net $32.0M, +12% vs Q2; Niktimvo collab $13.9M).
- Net loss $60.7M ($0.70/sh) vs $84.1M ($0.98/sh) year-ago; cash $456.1M.
- Revuforj FDA-approved for R/R NPM1m AML Oct 24, 2025; added to NCCN Guidelines as cat 2A.
- Full-year 2025 R&D+SG&A guidance narrowed to $380-$385M; expects to reach profitability.
- Total Revuforj prescriptions ~850 in Q3 (+25% vs Q2); Niktimvo net sales reported by Incyte $45.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000119312525262509/0001193125-25-262509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000119312525262509/sndx-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-262509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer